ClinicalTrials.gg
CompletedNCT01951235Updated Aug 13, 2015

A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes

A Phase 2 interventional study of Imeglimin and Placebo in Type 2 Diabetes Mellitus, sponsored by Poxel SA. Completed at 1 site in Latvia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-08-13.

Sponsored by Poxel SA · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
315
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Diabetes Mellitus, Type 2 with a site in Latvia — 2 open to participants now, 3 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Latvia.

Enrollment
51st of 58
315 · median 886
Started
2013
with 3 others
Phase 2
16 of 59
none open now
Registered
43rd of 59
by date

Among the 59 studies in Diabetes Mellitus, Type 2 with a site in Latvia, this one is the 51st largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2013, is one of 16 in phase 2, and was the 43rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 59 studies in Diabetes Mellitus, Type 2 with a site in Latvia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Latvia have not opened yet or have stopped. Only those recruiting at a site in Latvia →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Diabetes Mellitus, Type 2 with a site in Latvia, or all of them as a file.
02

Study summary

This study will assess the efficacy and safety/tolerability of 4 doses of Imeglimin versus placebo. The study will be performed in subjects with type 2 diabetes either naive of treatment or previously treated with an oral monotherapy excluding thiazolidinedione.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has given written
  2. Male and female type 2 diabetic subjects, either naïve of antidiabetic agents or treated with an oral anti-diabetic monotherapy.
  3. (BMI) : ≥ 24 to ≤ 40 kg/m²
  4. criteria: ≥ 7% and ≤ 9.5%
  5. ≥ 50 mL/[min*1.73 m2] at Screening Visit
  6. Effective for women of child bearing potential

Exclusion criteria

Exclusion Criteria:

  1. Any disease which in the investigator's opinion would exclude the subject from the study
  2. Acute cardiovascular event within 3 months before randomization
  3. Uncontrolled high blood pressure
  4. Impairment of hepatic function
  5. History of drug-induced Torsades de Pointes or a marked baseline prolongation of the
  6. Pregnancy or lactation
  7. Use of any non-permitted medication
  8. Positive screen for viral hepatitis
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
315 participants (actual)

Study arms

  • Experimental
    Imeglimin (Dose 1)

    Drug: Imeglimin

  • Experimental
    Imeglimin (Dose 2)

    Drug: Imeglimin

  • Experimental
    Imeglimin (Dose 3)

    Drug: Imeglimin

  • Experimental
    Imeglimin (Dose 4)

    Drug: Imeglimin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    Time frame: Baseline and week 24

Secondary outcomes

  1. Safety will be assessed by the incidence of adverse events (AEs), physical examination, relevant changes on laboratory tests, vital signs, and 12-lead electrocardiograms (ECG)

    Time frame: Baseline to week 24

07

Study locations

1 site
  • Pauls Stradins Clinical University Hospital
    Riga, Latvia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2013
First posted
Sep 26, 2013
Start
Jan 2013
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Results delay requested
Jul 2, 2015
Last update
Aug 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01951235
Lead sponsor
Poxel SA
Responsible party
Sponsor
First posted
Sep 26, 2013
Start date
Jan 2013
Primary completion
Jul 2014
Completion
Jul 2014
Last update
Aug 13, 2015

Study contacts

Valdis Pirags, MD
principal investigator · P. Stradins Clinical University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imeglimin

Start the discussion